Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Koa Shoji Holdings Co.,Ltd. (9273.T)
Yokohama, JP
Koa Shoji Holdings Co.,Ltd., established in 1991 and headquartered in Yokohama, Japan, operates through its subsidiaries, engaging in a diverse array of pharmaceutical activities. The company sources and distributes active pharmaceutical ingredients and their precursors throughout the Japanese market. Additionally, it is involved in the production and commercialization of a range of injectable medications, alongside over-the-counter drugs, with a particular emphasis on vitamin formulations. Koa Shoji Holdings also manufactures and distributes generic pharmaceuticals. Complementing these operations, the firm provides outsourced drug production services and offers specialized packaging solutions for medicinal products.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.41% | -2.75% | +2.66% | +1.07% | +4.94% | -0.59% | +26.72% | +15.83% | +10.26% | +182.60% | +182.60% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+5.1% Q1'26: +5.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+16.5% Q1'26: +6.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+11.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+23.2% ★ Q1'26: +24.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+23.3% ★ Q1'26: +19.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+6.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.40× ★ Q1'26: 0.42× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
14.83B
est: 12.78B (+16.0%)
|
15.21B
est: 15.45B (-1.6%)
|
16.03B
est: 15.80B (+1.5%)
|
17.82B
est: 17.80B (+0.1%)
|
20.35B
est: 20.70B (-1.7%)
|
22.05B
est: 22.10B (-0.2%)
|
22.13B
est: 22.90B (-3.3%)
|
23.27B
est: 24.30B (-4.2%)
|
25.40B
25.40B – 25.40B
+4.5% YoY
|
| EBITDA |
1.80B
est: 2.95B (-39.1%)
|
1.86B
est: 3.57B (-47.8%)
|
2.98B
est: 3.65B (-18.4%)
|
4.05B
est: 4.11B (-1.4%)
|
4.44B
est: 4.78B (-7.1%)
|
4.79B
est: 5.11B (-6.1%)
|
5.11B
est: 6.85B (-25.4%)
|
6.08B
est: 7.27B (-16.4%)
|
7.60B
7.60B – 7.60B
+4.5% YoY
|
| EBIT |
1.33B
est: 2.54B (-47.5%)
|
1.34B
est: 3.07B (-56.4%)
|
2.45B
est: 3.14B (-21.8%)
|
3.43B
est: 3.53B (-3.0%)
|
3.76B
est: 4.11B (-8.4%)
|
4.10B
est: 4.39B (-6.6%)
|
4.38B
est: 6.29B (-30.4%)
|
5.39B
est: 6.67B (-19.2%)
|
6.97B
6.97B – 6.97B
+4.5% YoY
|
| Net Income |
734.98M
est: 864.13M (-14.9%)
|
653.72M
est: 690.74M (-5.4%)
|
1.75B
est: 1.44B (+21.6%)
|
2.14B
est: 2.34B (-8.6%)
|
2.36B
est: 2.55B (-7.6%)
|
2.69B
est: 2.76B (-2.7%)
|
2.95B
est: 3.10B (-4.8%)
|
3.64B
est: 3.51B (+3.7%)
|
3.72B
3.72B – 3.72B
+6.0% YoY
|
| SGA |
2.13B
est: 1.35B (+57.4%)
|
2.48B
est: 1.63B (+51.7%)
|
2.34B
est: 1.67B (+40.3%)
|
2.17B
est: 1.88B (+15.4%)
|
2.13B
est: 2.19B (-2.8%)
|
2.19B
est: 2.34B (-6.1%)
|
2.26B
est: 2.42B (-6.7%)
|
2.34B
est: 2.57B (-8.8%)
|
2.68B
2.68B – 2.68B
+4.5% YoY
|
| EPS |
6.18
est: 20.52 (-69.9%)
|
16.50
est: 16.40 (+0.6%)
|
44.05
est: 34.08 (+29.3%)
|
53.94
est: 55.50 (-2.8%)
|
59.55
est: 60.60 (-1.7%)
|
67.83
est: 65.60 (+3.4%)
|
74.14
est: 73.50 (+0.9%)
|
86.38
est: 83.30 (+3.7%)
|
88.30
88.30 – 88.30
+6.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Militia Long/Short Equity ETF ORR | 0.14% | 188.0K | 14.19% |
| 2 | Amundi Japan TOPIX II UCITS ETF EUR Dist JPNU.L | 0.00% | 17.0K | 0.45% |
| 3 | iShares Core TOPIX ETF 1475.T | 0.00% | 183.7K | 0.05% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 44.8K | 0.28% |
| 5 | Avantis International Small Cap Value ETF AVDV | 0.00% | 62.8K | 0.36% |
| 6 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 38.3K | 0.22% |
| 7 | Dimensional - International Small Cap ETF DFIS | 0.00% | 10.2K | 0.39% |
| 8 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Miyoko Komatsu | MD of Finance & Accounting and Director | — | male |
| Ritsuko Ohtsuka | Executive Vice President, MD, Sustainability Officer & Director | — | female |
| Teruyuki Tanaka | Director of Business Development & Corporate Planning & Director | — | male |
| Toshihiro Hirono | MD & Director | — | male |
| Toshinori Koyama | Executive MD of Sales & Director | — | male |
| Toshiyuki Shuto | President, Chief Executive Officer & Chairman of the Board of Directors | — | male |
| Yuki Toyoda | Executive Officer & GM of the General Affairs Department | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9273.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
